ABSTRACT

A new, simple, rapid, economical, specific, precise and accurate method for simultaneous estimation of Olmesartan and Rosuvastatin in pure and their pharmaceutical combined dosage form has been developed and validated as per ICH Guidelines by using RP-HPLC. The separation was achieved by Develosil (C18) (150mm x 4.6mm) 5?m particle size column and Acetonitrile: Methanol: Phosphate Buffer(25:20:55v/v) used as mobile phase, at a flow rate of 1 ml/min. Detection was carried out at 248nm. The retention time of Olmesartan and Rosuvastatin was found to be 1.789 min and 3.488 min, respectively. The developed method was validated in terms of system suitability, selectivity, linearity, precision, accuracy, limits of detection, andquantification for the impurities following the ICH guidelines. Linearity was observed for Olmesartan (10-30?g/ml) and for Rosuvastatin (20-70?g/ml). The mean recovery for Olmesartan and Rosuvastatin is 100.43±0.107 and 100.25±0.211, respectively. The developed method was found to be simple, rapid, accurate, precise, and specific for the simultaneous estimation of Olmesartan and Rosuvastatin in pure and their pharmaceutical combined dosage form. Keywords: Olmesartan and Rosuvastatin, RP-HPLC, Accuracy, Precision, Robustness
Publication date: 01/10/2023

https://ijbpas.com/pdf/2023/October/MS_IJBPAS_2023_7466.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.10.7466